Together, these findings strongly suggest that CD27+CD28+ Temra cells reflect a unique ‘prequel’ of tumor-specific CD8+ T cell responses and can predict tumor prognosis and therapeutic efficacy of patients with cancer undergoing immunotherapy. This evidence concerns the gene CD27 and neoplasm.